Table 3 CircRNAs in non-platinum cytotoxic drugs
From: CircRNAs in anticancer drug resistance: recent advances and future potential
Cell cycle specificity | Drug | Cancer | CircRNAs | Mechanism | Role | Ref |
|---|---|---|---|---|---|---|
S phase | Irinotecan | Colorectal Cancer | circ_001680 | MiR-340/BMI1 axis | Up | [59] |
Pemetrexed | Gastric Cancer | circMTHFD2 | MiR-124/ FDZ5/MDR-1 axis | Up | [66] | |
Gemcitabine | Renal Cancer | circ_0035483 | MiR-335/CCNB1 axis | Up | [76] | |
Pancreatic Cancer | chr14:101402109–101,464,448+; chr4:52729603–52,780,244+; | Downregulate miR-145-5p | Up | [83] | ||
M phase | Taxol | Gastric cancer | circPVT1 | MiR-124-3p/ZEB1 axis | Up | [92] |
Ovarian Cancer | circ_0063809 | MiR-1252/ FOXR2 axis | Up | [98] | ||
Breast Cancer | circAMOTL1 | Activating AKT pathway | Up | [100] | ||
NSCLC | circ_0002483 | MiR-182-5p/GRB2/FOXO1/FOXO3 axis | Down | [106] | ||
Docetaxel | Lung Adenocarcinoma | circ_0003998 | Downregulate miR-326 | Up | [107] | |
Nasopharyngeal Carcinoma | circCRIM1 | MiR-422a/FOXQ1 axis | Up | [111] | ||
Cell cycle- nonspecific | Doxorubicin | Acute Myeloid Leukemia | circPAN3 | MiR-153-5p/miR-183-5p/XIAP axis | Up | [114] |
Breast Cancer | circ_0006528 | MiR-7–5p/ Raf1 axis | Up | [117] | ||
circKDM4C | MiR-548p/ PBLD axis | Down | [122] |